Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P42224: Variant p.Lys637Glu

Signal transducer and activator of transcription 1-alpha/beta
Gene: STAT1
Feedback?
Variant information Variant position: help 637 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Lysine (K) to Glutamate (E) at position 637 (K637E, p.Lys637Glu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (K) to medium size and acidic (E) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In IMD31A; affects both phosphorylation and DNA-binding activity; results in impaired STAT1-mediated cellular response to IFN-gamma and interleukin-27. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 637 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 750 The length of the canonical sequence.
Location on the sequence: help VERSQNGGEPDFHAVEPYTK K ELSAVTFPDIIRNYKVMAAE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         VERSQNGGEPDFHAVEPYTKKELSAVTFPDIIRNYKVMAAE

Mouse                         VERSQNGGEPDFHAVEPYTKKELSAVTFPDIIRNYKVMAAE

Pig                           VERSQNGGEPYFHAVEPYTKKELSAVTFPDIIRNYKVMAAE

Caenorhabditis elegans        VCEEADGQKIPFH-LAPFTIKDLDQLSLASRIASCPQL---

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 750 Signal transducer and activator of transcription 1-alpha/beta
Domain 573 – 670 SH2
Modified residue 637 – 637 N6-methyllysine
Modified residue 657 – 657 ADP-ribosyl glutamic acid; by PARP14
Mutagenesis 636 – 637 KK -> AA. No effect on IFN-alpha-induced STAT1 phosphorylation and nuclear translocation.
Mutagenesis 657 – 657 E -> Q. Loss of ADP-ribosylation and increased Tyr-701 phosphorylation; when associated with Q-705.
Helix 636 – 641



Literature citations
Dominant-negative STAT1 SH2 domain mutations in unrelated patients with Mendelian susceptibility to mycobacterial disease.
Tsumura M.; Okada S.; Sakai H.; Yasunaga S.; Ohtsubo M.; Murata T.; Obata H.; Yasumi T.; Kong X.F.; Abhyankar A.; Heike T.; Nakahata T.; Nishikomori R.; Al-Muhsen S.; Boisson-Dupuis S.; Casanova J.L.; Alzahrani M.; Shehri M.A.; Elghazali G.; Takihara Y.; Kobayashi M.;
Hum. Mutat. 33:1377-1387(2012)
Cited for: VARIANTS IMD31A GLU-637 AND ARG-673; CHARACTERIZATION OF VARIANTS IMD31A GLU-637 AND ARG-673;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.